logo
 COLL_logo
Driven by Xtampza ER and Belbuca®, we expect to immediately accelerate revenue growth making 2023 a banner year for Collegium. With our fully synergized cost structure, we expect significant bottom-line expansion, with adjusted EBITDA expected to grow at over four times the rate of adjusted operating expenses,” said Colleen Tupper, Chief Financial Officer of Collegium. “We are committed to deploying capital in a disciplined manner with business development as our highest priority

Collegium Provides 2023 Financial Guidance

Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2023 full-year financial guidance and provided a business update

By Collegium Pharmaceutical, Inc.
Published - Jan 04, 2023, 08:04 AM ET
Last Updated - Apr 02, 2024, 04:39 PM EDT

– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –

– Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million –

– Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million –

– $100 Million Share Repurchase Program Authorized by the Board of Directors –

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024